Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database.

IF 0.9 Q4 RESPIRATORY SYSTEM

Lung Cancer Management Pub Date : 2021-02-19 DOI:10.2217/lmt-2020-0028

Marta Soares, Luís Antunes, Patrícia Redondo, Marina Borges, Ruben Hermans, Dony Patel, Fiona Grimson, Robin Munro, Carlos Chaib, Laure Lacoin, Melinda Daumont, John R Penrod, John C O'Donnell, Maria José Bento, Francisco Rocha Gonçalves

{"title":"Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database.","authors":"Marta Soares, Luís Antunes, Patrícia Redondo, Marina Borges, Ruben Hermans, Dony Patel, Fiona Grimson, Robin Munro, Carlos Chaib, Laure Lacoin, Melinda Daumont, John R Penrod, John C O'Donnell, Maria José Bento, Francisco Rocha Gonçalves","doi":"10.2217/lmt-2020-0028","DOIUrl":null,"url":null,"abstract":"Aim: This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC).Materials & methods: Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016.Results: 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC.Conclusion: Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 2","pages":"LMT46"},"PeriodicalIF":0.9000,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/f5/lmt-10-46.PMC8162184.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2020-0028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC).

Materials & methods: Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016.

Results: 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC.

Conclusion: Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.

Abstract Image

查看原文本刊更多论文

早期非小细胞肺癌的治疗和结果:对一家葡萄牙医院数据库的回顾性分析。

目的:本观察性研究评估I-IIIA期非小细胞肺癌(NSCLC)患者的治疗模式和生存率。材料与方法:纳入2012-2016年IPO-Porto医院新诊断为NSCLC的成人。2015-2016年诊断的患者可获得治疗数据。结果:纳入495例患者(中位年龄:67岁)。最常见的治疗方法是单独手术或联合其他治疗(I期:66%)和全身抗癌治疗加放疗(II期:54%;IIIA期:59%)。I期、II期和IIIA期NSCLC(2012-2016年诊断)患者的1年OS (95% CI)分别为92%(88-96)、71%(62-82)和69% (63-75);接受治疗的I-II期或IIIA期NSCLC(2015-2016年诊断)患者的一年OS (95% CI)，非鳞状细胞为89%(81-97)和86%(75-98)，鳞状细胞NSCLC为76%(60-95)和49%(34-70)。结论:迫切需要I-IIIA期NSCLC的治疗进展，特别是对鳞状细胞组织学的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung Cancer Management RESPIRATORY SYSTEM-

CiteScore

2.30

自引率

0.00%

发文量